The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | A summary of lymphoma immune checkpoint inhibitor data at EHA 2017
Anas Younes, MD, from Memorial Sloan Kettering Cancer Center, NY, USA shares the latest data on immune checkpoint inhibitors presented during the summer congresses; ASCO, ICML and EHA. Included in his wrap up is the CHECKMATE 205 trial with nivolumab and the potential for targeting PDL-1 on which there was a Phase 1 trial presented at ICML. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
